| __timestamp | Eli Lilly and Company | Grifols, S.A. |
|---|---|---|
| Wednesday, January 1, 2014 | 6620800000 | 660772000 |
| Thursday, January 1, 2015 | 6533000000 | 736435000 |
| Friday, January 1, 2016 | 6452000000 | 775266000 |
| Sunday, January 1, 2017 | 6588100000 | 860348000 |
| Monday, January 1, 2018 | 5975100000 | 814775000 |
| Tuesday, January 1, 2019 | 6213800000 | 942821000 |
| Wednesday, January 1, 2020 | 6121200000 | 985616000 |
| Friday, January 1, 2021 | 6431600000 | 1061508000 |
| Saturday, January 1, 2022 | 6440400000 | 1190423000 |
| Sunday, January 1, 2023 | 6941200000 | 1254234000 |
| Monday, January 1, 2024 | 8593800000 |
Igniting the spark of knowledge
In the ever-evolving pharmaceutical industry, operational efficiency is key. Over the past decade, Eli Lilly and Company and Grifols, S.A. have demonstrated contrasting trends in their Selling, General, and Administrative (SG&A) expenses. Eli Lilly's SG&A expenses have shown a steady increase, peaking in 2023 with a 5% rise from 2022. This reflects their strategic investments in marketing and administration to maintain a competitive edge. Meanwhile, Grifols, S.A. has experienced a more dramatic growth, with their SG&A expenses nearly doubling from 2014 to 2023. This surge, particularly notable in the last three years, underscores Grifols' aggressive expansion and market penetration strategies. As these companies navigate the complexities of the global market, their SG&A trends offer a window into their operational priorities and future trajectories.
Gross Profit Analysis: Comparing Eli Lilly and Company and Grifols, S.A.
Selling, General, and Administrative Costs: Eli Lilly and Company vs Pharming Group N.V.
Operational Costs Compared: SG&A Analysis of Eli Lilly and Company and Axsome Therapeutics, Inc.
Comparing SG&A Expenses: Eli Lilly and Company vs Merus N.V. Trends and Insights
SG&A Efficiency Analysis: Comparing Eli Lilly and Company and Vericel Corporation
Comparing SG&A Expenses: AbbVie Inc. vs Grifols, S.A. Trends and Insights
Selling, General, and Administrative Costs: Bristol-Myers Squibb Company vs Grifols, S.A.
BioMarin Pharmaceutical Inc. vs Grifols, S.A.: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of Halozyme Therapeutics, Inc. and Grifols, S.A.
Breaking Down SG&A Expenses: Grifols, S.A. vs TG Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Grifols, S.A. and MorphoSys AG
Who Optimizes SG&A Costs Better? Grifols, S.A. or Iovance Biotherapeutics, Inc.